107 related articles for article (PubMed ID: 19818733)
1. An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas.
Fukamachi K; Tanaka H; Hagiwara Y; Ohara H; Joh T; Iigo M; Alexander DB; Xu J; Long N; Takigahira M; Yanagihara K; Hino O; Saito I; Tsuda H
Biochem Biophys Res Commun; 2009 Dec; 390(3):636-41. PubMed ID: 19818733
[TBL] [Abstract][Full Text] [Related]
2. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas.
Ueda S; Fukamachi K; Matsuoka Y; Takasuka N; Takeshita F; Naito A; Iigo M; Alexander DB; Moore MA; Saito I; Ochiya T; Tsuda H
Carcinogenesis; 2006 Dec; 27(12):2497-510. PubMed ID: 16774944
[TBL] [Abstract][Full Text] [Related]
3. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
Inami K; Kajino K; Abe M; Hagiwara Y; Maeda M; Suyama M; Watanabe S; Hino O
Oncol Rep; 2008 Dec; 20(6):1375-80. PubMed ID: 19020717
[TBL] [Abstract][Full Text] [Related]
4. Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.
Fukamachi K; Iigo M; Hagiwara Y; Shibata K; Futakuchi M; Alexander DB; Hino O; Suzui M; Tsuda H
PLoS One; 2014; 9(10):e111481. PubMed ID: 25347530
[TBL] [Abstract][Full Text] [Related]
5. Twenty-one proteins up-regulated in human H-ras oncogene transgenic rat pancreas cancers are up-regulated in human pancreas cancer.
Yabushita S; Fukamachi K; Kikuchi F; Ozaki M; Miyata K; Sukata T; Deguchi Y; Tanaka H; Kakehashi A; Kawamura S; Uwagawa S; Wanibuchi H; Suzui M; Alexander DB; Tsuda H
Pancreas; 2013 Aug; 42(6):1034-9. PubMed ID: 23648844
[TBL] [Abstract][Full Text] [Related]
6. Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.
Yabushita S; Fukamachi K; Tanaka H; Sumida K; Deguchi Y; Sukata T; Kawamura S; Uwagawa S; Suzui M; Tsuda H
Pancreas; 2012 Oct; 41(7):1013-8. PubMed ID: 22513294
[TBL] [Abstract][Full Text] [Related]
7. Ductal pancreatic cancer in humans and mice.
Tuveson DA; Hingorani SR
Cold Spring Harb Symp Quant Biol; 2005; 70():65-72. PubMed ID: 16869739
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
Fong ZV; Winter JM
Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
[TBL] [Abstract][Full Text] [Related]
9. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.
Maeda M; Hino O
Pathol Int; 2006 Nov; 56(11):649-54. PubMed ID: 17040286
[TBL] [Abstract][Full Text] [Related]
10. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
Adsay NV; Basturk O; Cheng JD; Andea AA
Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
[TBL] [Abstract][Full Text] [Related]
11. Metabolomic and transcriptomic profiling of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.
Yabushita S; Fukamachi K; Tanaka H; Fukuda T; Sumida K; Deguchi Y; Mikata K; Nishioka K; Kawamura S; Uwagawa S; Suzui M; Alexander DB; Tsuda H
Carcinogenesis; 2013 Jun; 34(6):1251-9. PubMed ID: 23393225
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.
Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K
J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230
[TBL] [Abstract][Full Text] [Related]
13. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
Qian J; Niu J; Li M; Chiao PJ; Tsao MS
Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547
[TBL] [Abstract][Full Text] [Related]
14. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
[TBL] [Abstract][Full Text] [Related]
15. K-ras mutation in focal proliferative lesions of human pancreas.
Terhune PG; Phifer DM; Tosteson TD; Longnecker DS
Cancer Epidemiol Biomarkers Prev; 1998 Jun; 7(6):515-21. PubMed ID: 9641496
[TBL] [Abstract][Full Text] [Related]
16. Where and when does pancreatic carcinoma start?
Lüttges J; Hahn S; Klöppel G
Med Klin (Munich); 2004 Apr; 99(4):191-5. PubMed ID: 15085289
[TBL] [Abstract][Full Text] [Related]
17. [Recent advances in diagnosis of pancreatic cancer].
Yamaguchi K; Ogawa Y; Yokohata K; Konomi H; Nakamura M; Nagata S; Tanaka M
Gan To Kagaku Ryoho; 2005 May; 32(5):612-6. PubMed ID: 15918559
[TBL] [Abstract][Full Text] [Related]
18. Molecular markers in pancreatic cancer diagnosis.
Herreros-Villanueva M; Gironella M; Castells A; Bujanda L
Clin Chim Acta; 2013 Mar; 418():22-9. PubMed ID: 23305796
[TBL] [Abstract][Full Text] [Related]
19. Laminin gamma2-chain fragment circulating level increases in patients with metastatic pancreatic ductal cell adenocarcinomas.
Katayama M; Funakoshi A; Sumii T; Sanzen N; Sekiguchi K
Cancer Lett; 2005 Jul; 225(1):167-76. PubMed ID: 15922869
[TBL] [Abstract][Full Text] [Related]
20. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.
Singh P; Srinivasan R; Wig JD
Pancreas; 2011 Jul; 40(5):644-52. PubMed ID: 21673535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
